CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59

Blood

Volumn 98, Issue 12, 2001, Pages 3383-3389

  Golay, Josée ^a,b   Lazzari, Manuela ^a,b   Facchinetti, Valeria ^a,b   Bernasconi, Sergio ^a,b   Borleri, Gianmaria ^a,b   Barbui, Tiziano ^a,b   Rambaldi, Alessandro ^a,b   Introna, Martino ^a,b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; COMPLEMENT; COMPLEMENT INHIBITOR; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; RITUXIMAB;

ARTICLE; B CELL LEUKEMIA; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CELL ISOLATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROTEIN EXPRESSION;

EID: 0035760902     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3383     Document Type: Article

References (28)

1. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66-73.
2. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol. 1999;26:74-78.
3. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol. 1999;26:88-96.
4. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol. 1999;26:79-87.
5. Dyer MJD. The role of Campath-1 antibodies in the treatment of lymphoid malignancies. Semin Oncol. 1999;26:52-57.
6. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678-3684.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
8. Glennie MS, Johnson PWM. Clinical trials of antibody therapy. Immunol Today. 2000;21:403-410.
9. Anderson DR, Grillo-Lopez A, Varns C, Chambers KS, Hanna N. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 1997;25:705-708.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
11. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908.
12. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634-641.
13. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
14. Mathas S, Rickers A, Bommert K, Doerken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signalling pathways. Cancer Res. 2000;60:7170-7176.
15. Ghetie M-A, Bright H, Vitetta E. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392-1398.
16. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.
17. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
18. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98:1326-1331.
19. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol. 1999;17:791-795.
20. Gazzano-Santoro H, Ralph P, Ryskamp TC, Chen AB, Mukku VR. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods. 1997;202:163-171.
21. Molica S, Levato D, Dattilo A, Mannella A. Clinicoprognostic relevance of quantitative immunophenotyping in B-cell chronic lymphocytic leukemia with emphasis on the expression of CD20 antigen and surface immunoglobulins. Eur J Haematol. 1998;60:47-52.
22. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51:364-369.
23. Rooney IA, Davies A, Morgan BP. Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology. 1992;75:499-506.
24. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol. 2000;11:117-121.
25. Hoffman M, Auerbach L. Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. Br J Haematol. 2000;109:900-901.
26. Liszewski M, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol. 1996;61:201-279.
27. Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol. 1999;62:247-250.
28. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.